CBCA Website   |   About CBCA   |   CBCA Mission   |   CBCA I.R.               Get FinancialNewsMedia.com News Alerts

Privacy Policy

Crown Baus Capital Corp. (OTC: CBCA) - August 1, 2014


CBCA News: Federal Medical Cannabis Legalization Efforts in Congress Motivates Crown Baus Capital to Initiate its Cannabis Drug Development Program With State-by-State Legal Resources


BEVERLY HILLS, California -- August 1, 2014 -- Crown Baus Capital Corp. (OTC: CBCA), a global acquisition-based conglomerate targeting five primary industries: high-tech incubation, drug development, entertainment/media, education, and financial services, sees this week's Congressional efforts to amend the Controlled Substances Act to permit medical use of cannabis on a nationwide basis as history in the making. This federal medical cannabis legalization effort in Congress motivates Crown Baus Capital to complete its negotiations to formally begin its Cannabis Drug Development Program using state-by-state legal resources and distribution.

The Company has already initiated drug development activity by negotiating to purchase property in several legal medical cannabis states across the country. This, coupled with the expertise of the Company's drug development partners, Crown Baus Capital expects to be able to fast track cannabis drug development to make these critical cannabis formulations available for those in need on a nationwide basis.

A group of bipartisan U.S. Representatives -- Scott Perry (R-Pennsylvania), Dana Rohrabacher (R-California), Steve Cohen (D-Tennessee), and Paul Broun, MD (R-Georgia) -- introduced a bill, H.R. 5226, to redefine "marijuana" on a federal legislative level to allow therapeutic, high-CBD cannabis oil to be used to treat seizure disorders. This is a major federal step towards the legalization of medical cannabis, which follows the approval of medical cannabis in nearly half of the states, with many more states actively pursuing legalization for medical and drug development purposes.

In addition, U.S. Senator Rand Paul (R-Kentucky) has announced that he will introduce a bill to reschedule cannabis from its Schedule 1 status under the Controlled Substances Act, so that cannabis can be properly researched, developed, and prescribed for medical purposes. Senator Paul has worked diligently through federal legislation to help states that have legalized medical cannabis.

"Our Drug Development Division's medical cannabis initiatives are strengthened by this week's progress in the U.S. House and Senate. These federal developments, in light of the rapid progress on the state level and overwhelming support for medical cannabis among the U.S. voting populace, provide critical forward momentum as the Company positions itself as a leader in the medical cannabis industry," said Chad S. Johnson, Director, President and CEO of CBCA.

About Crown Baus Capital Corp.
Crown Baus Capital Corp. (CBCA) is a global acquisition-based conglomerate targeting five primary industries: High-Tech Incubation, Drug Development, Entertainment/Media, Education, and Financial Services. The Company is based in the United States but is already operating globally through its subsidiary, WebCongress, Inc., and Company partners. Crown Baus seeks to add shareholder value through cross-industry synergies and strategic growth.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Crown Baus Capital Corp. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Chad S. Johnson, Esq., Director, President & CEO
info@crownbaus.com
www.crownbaus.com
+1 866.784.7239

Investment Inquiries
Robert Kane, Director & CFO
robert.kane@crownbaus.com
+1 561.420.4824


SOURCE: Crown Baus Capital Corp


Disclaimer

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which iis a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG was compensated one thousand five hundred dollars for Crown Baus Capital Corp. news coverage by the company.  FNMG HOLDS NO SHARES OF Direct View Holdings, Inc.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.